Advances in chemotherapy and targeted systemic therapies for Urothelial cancer
Advances in chemotherapy and targeted systemic therapies for Urothelial cancer
Systemic chemotherapy for cancer of the urothelial tract is used according to two main strategies. Neoadjuvant or adjuvant treatment combined with surgery and/or radiotherapy is aimed at cure of localised disease whilst treatment for advanced incurable disease allows for improved survival and palliation of symptoms. Cisplatin based combination regimens represent the standard of care in both of these settings and incorporation of gemcitabine has allowed for improvements in tolerability over older drugs. However, despite high objective response rates, impact on survival is modest. Targeted agents are now being incorporated into early phase clinical trials. These exciting new strategies hold promise for improved efficacy but with new challenges regarding toxicity profiles. This review will describe current evidence for the use of systemic chemotherapy for urothelial cancer and the state of the research evidence for use of the newer targeted agents.
urothelial cancer, bladder cancer, chemotherapy, systemic therapy
17-28
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Wheater, Matthew J.
3691c3d8-8589-4693-a0dc-c6a8648cd7df
February 2010
Crabb, Simon J.
bcd1b566-7677-4f81-8429-3ab0e85f8373
Wheater, Matthew J.
3691c3d8-8589-4693-a0dc-c6a8648cd7df
Crabb, Simon J. and Wheater, Matthew J.
(2010)
Advances in chemotherapy and targeted systemic therapies for Urothelial cancer.
Current Drug Therapy, 5 (1), .
Abstract
Systemic chemotherapy for cancer of the urothelial tract is used according to two main strategies. Neoadjuvant or adjuvant treatment combined with surgery and/or radiotherapy is aimed at cure of localised disease whilst treatment for advanced incurable disease allows for improved survival and palliation of symptoms. Cisplatin based combination regimens represent the standard of care in both of these settings and incorporation of gemcitabine has allowed for improvements in tolerability over older drugs. However, despite high objective response rates, impact on survival is modest. Targeted agents are now being incorporated into early phase clinical trials. These exciting new strategies hold promise for improved efficacy but with new challenges regarding toxicity profiles. This review will describe current evidence for the use of systemic chemotherapy for urothelial cancer and the state of the research evidence for use of the newer targeted agents.
This record has no associated files available for download.
More information
Published date: February 2010
Keywords:
urothelial cancer, bladder cancer, chemotherapy, systemic therapy
Identifiers
Local EPrints ID: 172835
URI: http://eprints.soton.ac.uk/id/eprint/172835
ISSN: 1574-8855
PURE UUID: 4b999cec-cd1c-42f0-976a-3c2733147614
Catalogue record
Date deposited: 31 Jan 2011 10:14
Last modified: 23 Jul 2022 01:51
Export record
Contributors
Author:
Matthew J. Wheater
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics